Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARR-002 · 1 trial · 5 indications
AEs that occur or worsen on or after the first dose of study treatment
Incidence of dose-limiting toxicities (DLTs) and serious adverse events (SAEs)
| Arm | Type | Description |
|---|---|---|
| ARR-002 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARR-002 | DRUG | ARR-002 will be administrated as specified in the protocol. |
Inclusion Criteria: * Patients with histologically and cytologically confirmed advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer, and platinum resistant who have failed or intolerant to standard therapy, or without alternative standard therapy. * Patients must have at lea...
Top 20 of 60 competitors
ARR-002 is an investigational therapy being studied for advanced or metastatic ovarian cancer, including platinum-resistant ovarian cancer, and for advanced or metastatic endometrial cancer. It is a small molecule in Phase 1 development and has not been approved for any use. All testing to date is in the clinical trial setting.
ARR-002 targets MUC16, also known as NaPi2b, a cell surface antigen. MUC16/NaPi2b is expressed on ovarian and endometrial tumor cells, making it an antigen-directed target for this small molecule. Targeting this antigen is the basis for the drug's proposed antitumor activity in the cancers under study.
ARR-002 is being developed by ArriVent BioPharma, Inc., which trades on the Nasdaq under the ticker AVBP. The company is the sponsor of the ongoing Phase 1 clinical program evaluating the agent in ovarian and endometrial cancer.
ARR-002 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. The single ongoing study is designed to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity in patients with advanced disease.
ARR-002 is being evaluated in one active clinical trial, NCT07755436, a Phase 1 study of safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity in advanced or metastatic ovarian or endometrial cancer. The trial is currently recruiting in the United States and plans to enroll approximately 180 female participants aged 18 years and older.